Whitney B Pope

List of Publications by Citations

161 papers	8,232 citations	49 h-index	88 g-index
167 ext. papers	9,492 ext. citations	4.4 avg, IF	5.87 L-index

#	Paper	IF	Citations
161	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncology, The*, **2015**, 16, e534-e542	21.7	425
160	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro-Oncology*, **2016**, 18, 1199-208	1	398
159	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. *Journal of Clinical Oncology*, **2011**, 29, 142-8	2.2	358
158	Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. *Journal of Clinical Oncology*, **2007**, 25, 4714-21	2.2	352
157	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. *Journal of Clinical Oncology*, **2011**, 29, 4482-90	2.2	337
156	MR imaging correlates of survival in patients with high-grade gliomas. *American Journal of Neuroradiology*, **2005**, 26, 2466-74	4.4	291
155	Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. *Radiology*, **2009**, 252, 182-9	20.5	271
154	18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. *Journal of Nuclear Medicine*, **2006**, 47, 904-11	8.9	264
153	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *Journal of Neuro-Oncology*, **2012**, 107, 197-205	4.8	237
152	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro-Oncology*, **2015**, 17, 1188-98	1	224
151	Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 1372-80	4	151
150	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. *Journal of Neuro-Oncology*, **2012**, 108, 491-8	4.8	134
149	Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. *Radiology*, **2008**, 249, 268-77	20.5	133
148	Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke - Comparison with dynamic susceptibility contrast enhanced perfusion imaging. *NeuroImage: Clinical*, **2013**, 3, 1-7	5.3	128
147	Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. *Radiology*, **2014**, 271, 200-10	20.5	121
146	The value of arterial spin-labeled perfusion imaging in acute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced MRI. *Stroke*, **2012**, 43, 1018-24	6.7	121
145	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. *Neuro-Oncology*, **2015**, 17, 1434-44	1	116

144	3Q-deoxy-3Q-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. *Journal of Nuclear Medicine*, **2012**, 53, 29-36	8.9	110
143	Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. *Clinical Cancer Research*, **2014**, 20, 3550-9	12.9	97
142	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. *NeuroImage*, **2012**, 59, 908-16	7.9	97
141	Time course of imaging changes of GBM during extended bevacizumab treatment. *Journal of Neuro-Oncology*, **2008**, 88, 339-47	4.8	96
140	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. *Journal of Neuro-Oncology*, **2017**, 134, 495-504	4.8	95
139	Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. *Clinical Cancer Research*, **2007**, 13, 2592-8	12.9	92
138	Advances in MRI assessment of gliomas and response to anti-VEGF therapy. *Current Neurology and Neuroscience Reports*, **2011**, 11, 336-44	6.6	89
137	18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. *European Journal of Radiology*, **2009**, 71, 242-8	4.7	87
136	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. *Neuro-Oncology*, **2012**, 14, 1079-89	1	84
135	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. *Journal of Neuro-Oncology*, **2017**, 134, 177-188	4.8	83
134	Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. *Experimental Neurology*, **1994**, 126, 185-94	5.7	82
133	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. *Neuro-Oncology*, **2013**, 15, 370-81	1	81
132	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. *Neuro-Oncology*, **2011**, 13, 401-9	1	81
131	BI-10pH-WEIGHTED MRI IN HUMAN GLIOMAS. *Neuro-Oncology*, **2014**, 16, v25-v25	1	78
130	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. *Neuro-Oncology*, **2013**, 15, 626-34	1	78
129	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. *NeuroImage: Clinical*, **2017**, 13, 386-394	5.3	76
128	Brain metastases: neuroimaging. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 149, 89-112	3	76
127	Engagement of fusiform cortex and disengagement of lateral occipital cortex in the acquisition of radiological expertise. *Cerebral Cortex*, **2009**, 19, 2746-54	5.1	76

126	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. *Neuro-Oncology*, **2015**, 17, 1514-24	1	73
125	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. *Journal of Neuro-Oncology*, **2014**, 116, 373-9	4.8	73
124	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. *Journal of Neuro-Oncology*, **2010**, 96, 359-67	4.8	72
123	PET imaging in patients with brain metastasis-report of the RANO/PET group. *Neuro-Oncology*, **2019**, 21, 585-595	1	72
122	Safety of anticoagulation use and bevacizumab in patients with glioma. *Neuro-Oncology*, **2008**, 10, 355-60	1	71
121	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. *Neuro-Oncology*, **2012**, 14, 333-43	1	69
120	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. *Neuro-Oncology*, **2011**, 13, 1151-61	1	61
119	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2017**, 40, 228-234	2.7	60
118	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. *Neuro-Oncology*, **2014**, 16, 414-20	1	60
117	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. *Journal of Neuro-Oncology*, **2012**, 106, 111-9	4.8	56
116	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. *Journal of Magnetic Resonance Imaging*, **2012**, 35, 1472-7	5.6	55
115	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. *Neuro-Oncology*, **2016**, 18, 467-78	1	51
114	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). *Neuro-Oncology*, **2015**, 17, v158.4-v159	1	50
113	Supraaortic arteries: contrast-enhanced MR angiography at 3.0 T--highly accelerated parallel acquisition for improved spatial resolution over an extended field of view. *Radiology*, **2007**, 242, 600-9	20.5	50
112	Blood-Labyrinth Barrier Permeability in Meniere Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI. *American Journal of Neuroradiology*, **2016**, 37, 1903-1908	4.4	49
111	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. *Neuro-Oncology*, **2017**, 19, 89-98	1	48
110	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. *Clinical Cancer Research*, **2016**, 22, 575-81	12.9	47
109	High spatial-resolution CE-MRA of the carotid circulation with parallel imaging: comparison of image quality between 2 different acceleration factors at 3.0 Tesla. *Investigative Radiology*, **2006**, 41, 391-9	10.1	47

108	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. *Clinical Cancer Research*, **2017**, 23, 5745-5756	12.9	44
107	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. *Neuro-Oncology*, **2020**, 22, 17-30	1	43
106	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. *Neuro-Oncology*, **2014**, 16, 815-22	1	41
105	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. *NMR in Biomedicine*, **2016**, 29, 1563-1576	4.4	40
104	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. *Neuro-Oncology*, **2018**, 20, 1240-1250	1	39
103	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). *Neuro-Oncology*, **2014**, 16 Suppl 7, vii36-47	1	38
102	Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. *Journal of Neuroimaging*, **2014**, 24, 23-30	2.8	38
101	Phosphorylated tau epitope of Alzheimer's disease is coupled to axon development in the avian central nervous system. *Experimental Neurology*, **1993**, 120, 106-13	5.7	38
100	Contrast-enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time-of-flight MR angiography. *American Journal of Neuroradiology*, **2006**, 27, 2118-21	4.4	38
99	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. *Neuro-Oncology*, **2019**, 21, 837-853	1	37
98	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. *Cancer*, **2016**, 122, 1718-27	6.4	37
97	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 62, 239-253	1.4	37
96	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. *Neuro-Oncology*, **2013**, 15, 382-90	1	36
95	Nitroxoline induces apoptosis and slows glioma growth in vivo. *Neuro-Oncology*, **2015**, 17, 53-62	1	34
94	Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. *Magnetic Resonance in Medicine*, **2012**, 67, 237-45	4.4	34
93	Emerging techniques and technologies in brain tumor imaging. *Neuro-Oncology*, **2014**, 16 Suppl 7, vii12-23	1	33
92	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. *Neuro-Oncology*, **2012**, 14, 1465-72	1	33
91	Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. *Magnetic Resonance Imaging Clinics of North America*, **2016**, 24, 649-670	1.6	32

90	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. *Journal of Neuro-Oncology*, **2011**, 105, 91-101	4.8	32
89	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. *Journal of Neuro-Oncology*, **2015**, 122, 497-505	4.8	31
88	Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). *Magnetic Resonance in Medicine*, **2018**, 80, 1962-1978	4.4	30
87	3-T contrast-enhanced MR angiography in evaluation of suspected intracranial aneurysm: comparison with MDCT angiography. *American Journal of Roentgenology*, **2008**, 190, 389-95	5.4	30
86	Two cases of rheumatoid meningitis. *Neuropathology*, **2016**, 36, 93-102	2	30
85	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 1195-1203	4	29
84	Genomics of brain tumor imaging. *Neuroimaging Clinics of North America*, **2015**, 25, 105-19	3	28
83	F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. *Journal of Neuro-Oncology*, **2018**, 139, 399-409	4.8	28
82	Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. *Human Pathology*, **2013**, 44, 1177-83	3.7	28
81	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. *European Journal of Radiology*, **2017**, 97, 31-36	4.7	27
80	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. *Molecular Imaging and Biology*, **2015**, 17, 434-42	3.8	27
79	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. *American Journal of Neuroradiology*, **2016**, 37, 1440-6	4.4	26
78	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. *Journal of Magnetic Resonance Imaging*, **2016**, 44, 1229-1237	5.6	25
77	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. *IScience*, **2020**, 23, 101453	6.1	22
76	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. *Cancer Imaging*, **2014**, 14, 31	5.6	19
75	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. *Clinical Cancer Research*, **2015**, 21, 4373-83	12.9	18
74	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. *Journal of Neuro-Oncology*, **2018**, 139, 651-659	4.8	18
73	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. *Scientific Reports*, **2019**, 9, 2846	4.9	17

72	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. *CNS Oncology*, **2013**, 2, 33-47	4	16
71	Between-Scanner and Between-Visit Variation in Normal White Matter Apparent Diffusion Coefficient Values in the Setting of a Multi-Center Clinical Trial. *Clinical Neuroradiology*, **2016**, 26, 423-430	2.7	15
70	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. *Neuro-Oncology*, **2019**, 21, 1184-1196	1	15
69	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. *Journal of Neuro-Oncology*, **2019**, 142, 587-595	4.8	15
68	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. *American Journal of Neuroradiology*, **2019**, 40, 979-986	4.4	14
67	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. *NeuroImage: Clinical*, **2015**, 9, 617-24	5.3	14
66	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. *CNS Oncology*, **2015**, 4, 247-56	4	13
65	Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis?. *Neuropathology*, **2017**, 37, 233-240	2	13
64	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. *Cancer Science*, **2016**, 107, 1110-6	6.9	13
63	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. *Neuro-Oncology*, **2018**, 20, 1525-1535	4	12
62	Gadolinium Deposition within the Pediatric Brain: No Increased Intrinsic T1-Weighted Signal Intensity within the Dentate Nucleus following the Administration of a Minimum of 4 Doses of the Macrocyclic Agent Gadoteridol. *American Journal of Neuroradiology*, **2018**, 39, 1604-1608	4.4	12
61	Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. *Tomography*, **2018**, 4, 123-137	3.1	12
60	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. *Scientific Reports*, **2020**, 10, 11922	4.9	12
59	Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol. *European Radiology*, **2018**, 28, 4882-4889	8	11
58	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. *Journal of Neuro-Oncology*, **2013**, 112, 257-66	4.8	11
57	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. *American Journal of Neuroradiology*, **2018**, 39, 43-45	4.4	10
56	Ensemble segmentation for GBM brain tumors on MR images using confidence-based averaging. *Medical Physics*, **2013**, 40, 093502	4.4	10
55	Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease. *Journal of Neurology*, **2010**, 257, 839-42	5.5	10

54	Rate of change in maximum F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. *Journal of Neuro-Oncology*, **2020**, 147, 135-145	4.8	9
53	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. *Journal of Neuro-Oncology*, **2014**, 116, 551-8	4.8	9
52	Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. *Tomography*, **2015**, 1, 37-43	3.1	9
51	Voxelwise and Patientwise Correlation of F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. *Journal of Nuclear Medicine*, **2021**, 62, 319-325	8.9	9
50	High order diffusion tensor imaging in human glioblastoma. *Academic Radiology*, **2011**, 18, 947-54	4.3	8
49	Using non-invasive neuroimaging to enhance the care, well-being and experimental outcomes of laboratory non-human primates (monkeys). *NeuroImage*, **2021**, 228, 117667	7.9	8
48	C-terminally truncated form of Bb-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. *Journal of Neuro-Oncology*, **2014**, 117, 53-65	4.8	7
47	Neuroimaging. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2016**, 134, 27-50	3	6
46	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. *Journal of Neuro-Oncology*, **2014**, 116, 601-8	4.8	6
45	CADrx for GBM Brain Tumors: Predicting Treatment Response from Changes in Diffusion-Weighted MRI. *Algorithms*, **2009**, 2, 1350-1367	1.8	6
44	Evaluation of Magnetonanoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI. *Applied Biochemistry and Biotechnology*, **2017**, 183, 265-279	3.2	5
43	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. *PET Clinics*, **2013**, 8, 201-17	2.2	5
42	A novel bicompartmental mathematical model of glioblastoma multiforme. *International Journal of Oncology*, **2015**, 46, 825-32	4.4	5
41	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. *Oncology Reports*, **2015**, 33, 2883-8	3.5	5
40	Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. *Human Pathology*, **2009**, 40, 1200-4	3.7	5
39	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. *PET Clinics*, **2013**, 8, 163-82	2.2	4
38	Functionalized magnetonanoparticles in visualization of intracranial tumors on MRI. *Molecular Imaging and Biology*, **2013**, 15, 299-306	3.8	4
37	Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. *Pharmacogenomics and Personalized Medicine*, **2010**, 3, 79-85	2.1	4

36	A methodology to integrate clinical data for the efficient assessment of brain-tumor patients. *Informatics for Health and Social Care*, **2008**, 33, 55-68	2.7	4
35	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. *Journal of Neuro-Oncology*, **2020**, 149, 337-346	4.8	4
34	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. *Cancer Imaging*, **2021**, 21, 27	5.6	4
33	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. *Neuroradiology*, **2021**, 63, 857-868	3.2	4
32	The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China. *Frontiers in Oncology*, **2020**, 10, 852	5.3	3
31	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. *Journal of Neuro-Oncology*, **2020**, 147, 643-652	4.8	3
30	Histogram-based classification with Gaussian mixture modeling for GBM tumor treatment response using ADC map **2009**,		3
29	Radiomics for precision medicine in glioblastoma.. *Journal of Neuro-Oncology*, **2022**, 156, 217	4.8	3
28	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. *Journal of Clinical Oncology*, **2014**, 32, 2007-2007	2.2	3
27	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. *Scientific Reports*, **2020**, 10, 14819	4.9	3
26	Standardized Brain Tumor Imaging Protocol for Clinical Trials. *American Journal of Neuroradiology*, **2015**, 36, E65-6	4.4	2
25	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. *Neurosurgery*, **2020**, 87, 931-938	3.2	2
24	Intraoperative mass spectrometry of tumor metabolites. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10906-7	11.5	2
23	Evidence for rCBV as an early response marker following bevacizumab treatment. *Neuro-Oncology*, **2015**, 17, 1539-40	1	2
22	Sampling-based ensemble segmentation against inter-operator variability **2011**,		2
21	Transient expression of adheron molecules during chick retinal development. *Journal of Neurobiology*, **1992**, 23, 720-38		2
20	Current concepts in brain tumor imaging. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 119-24	7.1	1
19	Confidence-based ensemble for GBM brain tumor segmentation **2011**,		1

18	Activity in the fusiform face area supports expert perception in radiologists and does not depend upon holistic processing of images **2009**,		1
17	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.. *Scientific Reports*, **2022**, 12, 1078	4.9	1
16	Preferential tumor localization in relation to F-FDOPA uptake for lower-grade gliomas. *Journal of Neuro-Oncology*, **2021**, 152, 573-582	4.8	1
15	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. *Annals of Nuclear Medicine*, **2021**, 35, 1022-1029	2.5	1
14	Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy. *Journal of Neuroradiology*, **2020**, 47, 166-173	3.1	1
13	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). *Brain Imaging and Behavior*, **2021**, 1	4.1	1
12	"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging.. *NeuroImage: Clinical*, **2021**, 32, 102882	5.3	0
11	Imaging Advances for Central Nervous System Tumors. *Hematology/Oncology Clinics of North America*, **2022**, 36, 43-61	3.1	0
10	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. *Cancers*, **2022**, 14, 2520	6.6	0
9	Isolated choroid plexus granulomas: initial presentation of neurosarcoidosis?. *Canadian Journal of Neurological Sciences*, **2014**, 41, 112-4	1	
8	Brainstem Gliomas **2013**, 18, 237-242		
7	NIMG-74. RESPONSE ASSESSMENT AFTER DOSE-ESCALATED RADIOTHERAPY: IMAGING PROTOCOL OF A MULTICENTER PHASE III TRIAL ON INTRAOPERATIVE RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA (INTRAGO-II;ARO2016-1;AG-NRO-03). *Neuro-Oncology*, **2021**, 23, vi146-vi146	1	
6	NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS. *Neuro-Oncology*, **2021**, 23, vi138-vi138	1	
5	Molecular Imaging of Diffuse Low Grade Glioma **2017**, 173-195		
4	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.. *Frontiers in Oncology*, **2022**, 12, 849993	5.3	
3	NIMG-36. VISUALIZATION OF TUMOR HETEROGENEITY AND PREDICTION OF ISOCITRATE DEHYDROGENASE MUTATION STATUS FOR HUMAN GLIOMAS BY USING MULTIPARAMETRIC PHYSIOLOGIC AND METABOLIC MRI. *Neuro-Oncology*, **2021**, 23, vi136-vi137	1	
2	NIMG-44. PROGNOSTIC VALUE OF PH- AND OXYGEN-SENSITIVE MRI IN GLIOMA PATIENTS. *Neuro-Oncology*, **2021**, 23, vi138-vi139	1	
1	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. *Tomography*, **2022**, 8, 1437-1452	3.1	